1,419,185 research outputs found
To switch or not to switch after a poor response to a TNFα blocker? It is not only a matter of ACR20 OR ACR50
No full textThe introduction in the therapeutic armamentarium of TNF inhibitors (TNFi) has greatly advanced the chance of obtaining a control of clinical manifestations and of structural damage progression in an important proportion of patients with rheumatoid arthritis (RA) Methotrexate (MTX)-poor responders. However not more than 50% of TNFi treated patients can reach relevant clinical benefits. Therefore the unmet medical question is: should we continue the therapeutic approach with a second or a third TNFi, or should we use other drugs, and change the mode of action of the second drug? These are practical issues that still do not have a definite answer. The real problem is that up to this moment no real biomarker is available to make the appropriate choice. The only clear-cut biomarker is represented by the positivity of rheumatoid factor (RF) or anti citrullinated peptide autoantibodies (ACPA). Seropositive patients seem to respond better than seronegative ones to B cell depletion therapy (Rituximab). This paper discusses the pros and cons of switching or swapping in RA patients poorly responder to the first TNFi
Ryhiner-Kartensammlung / 25/A [Titelblatt und Ansicht von Nürnberg (Roth)]
No full textCph: Melch: Roth inv: del: et sculpsTitelblatt von: "Prospecte aller Nürnbergischen Städtlein, Markt=Flecken und Pfarr=Dörffer" von Christoph Melchior Roth (Nürnberg : C.M. und M. Roth, 1760
A genealogical study of the Nicolaus and Veronica (Zimerman) Roth family, 1834-1954 /
No full textPublished under auspices of the Daniel Roth Family Reunion.Includes bibliographical references and index.Mode of access: Internet
Ryhiner-Kartensammlung / 33/A Carthæuser-Kloster Marien Zell, genannt in Nurnberg
No full textC.M. Roth excud: Norib.Titel oben rechtsUrsprungswerk: "Chr. Melch. Roths dreyssig sowohl innere als äussere Abbildungen aller Kirchen, Klöster und Kapellen in Nürnberg" von Christoph Melchior Roth (Nürnberg, um 1760
Ryhiner-Kartensammlung / 32/A Die Kirche zu St. Mariæ in Nürnberg
No full textC.M. Roth excud.Titel oben MitteUrsprungswerk: "Chr. Melch. Roths dreyssig sowohl innere als äussere Abbildungen aller Kirchen, Klöster und Kapellen in Nürnberg" von Christoph Melchior Roth (Nürnberg, um 1760
Ryhiner-Kartensammlung / 35/E Die neuerbaute und A[nn]o 1618 vollendete St. Egydien Kirche in Nürnberg von Innen gegen den Chor anzusehen
No full textC.M. Roth excud: Norib.Titel untenUrsprungswerk: "Chr. Melch. Roths dreyssig sowohl innere als äussere Abbildungen aller Kirchen, Klöster und Kapellen in Nürnberg" von Christoph Melchior Roth (Nürnberg, um 1760
Ernest Roth Collection-World War I
No full textThe collection consists of a transcribed reminiscence and diary entries for Ernest Roth from Columbia (S.D.) and his military service as a member of Company D, 151 Machine Gun Battalion, 42nd Rainbow Division. The reminiscence was requested and compiled by his family in December of 1967. The reminiscence and diary entries includes his enlistment, basic training, combat in Europe and return back to the states, dating from April 1917 to February 1919. The reminiscence concludes with a newspaper clipping with photo of a letter sent by Roth from France written October 6, 1918
John Roth
No full textMr. Roth currently serves as the Vice President of Business Development for Sierra Nevada Space Systems where he is responsible for new business acquisition and customer relations for all product lines which include Spacecraft, Propulsion, Space Technologies, and Space Exploration. Mr. Roth served as President of MicroSat Systems Inc. from 2002 until its acquisition by Sierra Nevada Corporation in 2008.
Prior to joining MicroSat Systems, Mr. Roth was Vice President of the Electronic Combat Business Unit for Litton Advanced Systems. Programs under his leadership included major defense systems such as the Joint Strike Fighter Electronic Warfare suite, ICAP III electronic warfare suite for the Navy E-2C carrier aircraft, and the Advanced Integrated Electronic Warfare System (AIEWS) for Navy surface ships. Prior to joining Litton, Mr. Roth was Director of Colorado Springs Operations for Lockheed Martin Electronic Defense Systems which provided direct support to the Air Force Space Command’s Space Warfare Center at Falcon AFB. Mr. Roth has also held positions at Litton Amecom as Director of Advanced Programs, at HRB-Singer as Electronic Warfare Programs Manager, and at Hughes Aircraft Ground Systems Group as Manager of the Processor Architecture group.
Mr. Roth holds a BS in Computer Science Engineering from the University of Illinois and an MS in Electrical Engineering from the University of Southern California. He has attended the Harvard Business School Executive Education program in Management and Leadership and the Wharton Business School Executive Education Program in Finance and has served on the board of directors of the Colorado Space Business Roundtable, the Advisory Board of the Colorado Space Grant Consortium, the National Executive Space Council for the Aerospace Industries Association (AIA), and the Board of Directors for the Center for Space Entrepreneurship. Mr. Roth is an Associate Fellow of the American Institute of Aeronautics and Astronautics (AIAA) and is a Corresponding Member of the International Academy of Astronautics.https://commons.erau.edu/space-congress-bios-2018/1053/thumbnail.jp
Tomographic particle-image velocimetry measurements in a turbulent wavy channel flow
No full textTo investigate small scale turbulent structures and their statistical properties in non-isotropic turbulent flow subjected to favorable and adverse pressure gradients, a novel method to divide the instantaneous flow field into strictly monotonic elements is applied to tomographic particle-image velocimetry data.Especially the scaling regimes of velocity differences within each element with respect to their lengths are considered
Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)
No full textOBJECTIVE:
To evaluate the efficacy and safety of three dosing and repeat treatment regimens of rituximab (RTX) plus MTX in patients with active RA.
METHODS:
Patients with active RA despite stable MTX (10-25 mg/week) were randomly assigned to one of the three treatment regimens comprising two courses of RTX given 24 weeks apart: 2 x 500 and 2 x 500 mg; 2 x 500 and 2 x 1000 mg (dose escalation); and 2 x 1000 and 2 x 1000 mg. The primary endpoint was proportion of patients achieving ACR20 at Week 48.
RESULTS:
At Week 48, ACR20 responses were not statistically significantly different between the dose regimens. Compared with RTX 2 x 500 mg (n = 134) or dose escalation (n = 119), ACR and European League Against Rheumatism (EULAR) outcomes in the RTX 2 x 1000 mg group (n = 93) were consistently higher, with significantly more patients achieving EULAR responses (P = 0.0495). At Week 48, rituximab 2 x 1000 mg was associated with a higher proportion of patients who, following retreatment, maintained or improved their Week 24 responses. Dose escalation from 2 x 500 to 2 x 1000 mg did not appear to be associated with improved outcomes compared with continual 2 x 500 mg. All RTX regimens demonstrated comparable safety.
CONCLUSIONS:
RTX 2 x 500 and 2 x 1000 mg could not be clearly differentiated, although some efficacy outcomes suggest improved outcomes in the rituximab 2 x 1000 mg group. Retreatment from Week 24 resulted in a sustained suppression of disease activity through to Week 48
- …
